ELI LILLY AND COMPANY Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31)
ELI LILLY AND COMPANY (LLY) reported Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) of $77.80 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-04-29.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet · last filed 2016-04-29
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2016-03-31 was $77.80M.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2015-03-31 was $0.00.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2011-09-30 was $15.50M.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2013 was $16.70M.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 3 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 6 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 9 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2016-03-31 | $77.80M 10-Q · filed 2016-04-29 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-04-29 | |||
| 2013-12-31 | $16.70M 10-K · filed 2014-02-19 | |||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-26 | $0.00 10-Q · filed 2012-10-26 | ||
| 2012-06-30 | $0.00 10-Q · filed 2012-07-27 | |||
| 2011-09-30 | $15.50M 10-Q · filed 2012-10-26 | $51.30M derived: sum of 2 quarters · filed 2012-10-26 | $41.20M 10-Q · filed 2012-10-26 | |
| 2011-06-30 | $35.80M 10-Q · filed 2012-07-27 | $25.80M 10-Q · filed 2012-07-27 | ||
| 2011-03-31 | $10.00M 10-Q · filed 2012-04-30 | |||
| 2010-06-30 | $0.00 10-Q/A · filed 2010-08-02 | $0.00 10-Q/A · filed 2010-08-02 | ||
| 2009-06-30 | $37.80M 10-Q/A · filed 2010-08-02 | $37.80M 10-Q/A · filed 2010-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |